What is Alcala Labs?
Alcala Labs operates as a specialized diagnostic facility providing comprehensive toxicology, pharmacogenetics, and blood wellness testing services. The organization distinguishes itself through a robust portfolio of analytical methods, including urine, serum, plasma, and dried blood spot testing. By integrating advanced scientific methodologies with a focus on customer-centric service, Alcala Labs serves a diverse clientele ranging from individual health-conscious consumers to medical professionals requiring precise medication quantification and respiratory pathogen detection. Their infrastructure is designed to meet the rigorous demands of modern healthcare, ensuring reliable data delivery for health assessments and regulatory compliance requirements.
How much funding has Alcala Labs raised?
Alcala Labs has raised a total of $150K across 1 funding round:
Debt
$150K
Debt (2020): $150K with participation from PPP
Key Investors in Alcala Labs
PPP
Public-Private Partnership
What's next for Alcala Labs?
With the successful acquisition of this capital, Alcala Labs is poised to accelerate its strategic growth initiatives. The firm is expected to leverage these resources to expand its laboratory capacity and refine its diagnostic throughput, particularly in the high-demand sectors of pharmacogenetics and drug abuse screening. As the company transitions through this late-stage funding cycle, the focus will likely shift toward technological integration and the optimization of its testing supply chain. By prioritizing operational efficiency and scientific innovation, Alcala Labs aims to capture a larger share of the clinical diagnostics market, reinforcing its reputation as a reliable partner for medical practitioners and individual patients alike.
See full Alcala Labs company page
